Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?Amanda Mocroft, J. Kosmidis, Jürgen K. Rockstroh et al.|Antiviral Therapy|2005Cited by 30
Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to AmprenavirTN Nguyen, François Clavel, Dominique Costagliola et al.|Antiviral Therapy|2004Cited by 21
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD TrialsErkki Lathouwers, Renato Maserati, Eric Wong et al.|AIDS Research and Human Retroviruses|2019Cited by 14